Sanofi | SNY
Stock Price
54.46
Daily Change
0.46 0.84%
Monthly
10.04%
Yearly
17.39%
Q1 Forecast
53.51



Peers Price Chg Day Year Date
AbbVie 192.98 -0.58 -0.30% 9.28% Feb/14
Amgen 291.46 -5.66 -1.91% 0.83% Feb/14
AstraZeneca 11,662.00 -46.00 -0.39% 11.94% Feb/17
Bristol-Myers Squibb 53.85 -2.04 -3.65% 8.92% Feb/14
Corcept Therapeutics 72.72 -0.89 -1.21% 197.30% Feb/14
Genmab 1,503.50 -0.50 -0.03% -26.05% Feb/17
Galapagos 24.38 0.46 1.92% -33.77% Feb/17
GlaxoSmithKline 1,418.50 -16.50 -1.15% -15.02% Feb/17
Glaxosmithkline 36.17 -0.38 -1.04% -13.41% Feb/14
Indivior 789.50 -2.50 -0.32% -44.71% Feb/14
J&J 156.20 -1.04 -0.66% -1.09% Feb/14
Eli Lilly 844.94 -28.28 -3.24% 11.50% Feb/14
Merck 83.02 -1.34 -1.59% -34.39% Feb/14
Novartis 95.52 0.15 0.16% 6.65% Feb/17
Novartis 105.43 -2.12 -1.97% 6.44% Feb/14
Prestige Brands 86.00 0.32 0.37% 25.04% Feb/14
Pacira 25.44 -1.09 -4.11% -14.23% Feb/14
Pfizer 25.50 -0.15 -0.58% -7.31% Feb/14
Perrigo 24.54 -0.26 -1.04% -22.24% Feb/14
Drreddys Laboratories 13.60 -0.39 -2.79% -81.87% Feb/14
Roche Holding 295.50 1.00 0.34% 27.37% Feb/17
Sanofi 54.46 0.46 0.84% 17.39% Feb/14
Supernus Pharmaceuticals 39.11 -0.42 -1.06% 36.46% Feb/14
UCB 182.80 2.35 1.30% 91.61% Feb/17
Canopy Growth 2.68 0 0% -44.51% Feb/14
Zoetis 157.54 -7.69 -4.65% -16.93% Feb/14

Sanofi traded at $54.46 this Friday February 14th, increasing $0.46 or 0.84 percent since the previous trading session. Looking back, over the last four weeks, Sanofi gained 10.04 percent. Over the last 12 months, its price rose by 17.39 percent. Looking ahead, we forecast Sanofi to be priced at 53.51 by the end of this quarter and at 51.26 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.